Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dangerous small B-cell clones.

Giampaolo Merlini1, Marvin J Stone

  • 1Amyloid Center, Biotechnology Research Laboratories, Foundation IRCCS Policlinico San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy. gmerlini@smatteo.pv.it

Blood
|June 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifaceted effects of N-glycosylation on amyloidogenic κ light chains in AL amyloidosis.

Structure (London, England : 1993)·2026
Same author

A Phase 2 trial of daratumumab monotherapy in newly diagnosed patients with cardiac stage IIIb AL amyloidosis.

Blood·2026
Same author

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Blood·2026
Same author

Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.

JACC. CardioOncology·2026
Same author

Current Standards and Perspectives in Proteomics for Cardiac Amyloidosis.

Analytical chemistry·2026
Same author

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

HemaSphere·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Small B-cell clones can produce toxic monoclonal proteins causing severe systemic diseases. Early diagnosis of these rare monoclonal component-related diseases is crucial for effective treatment and improved patient outcomes.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Monoclonal immunoglobulins typically indicate B-cell clone expansion.
  • Small clones can produce highly toxic proteins, leading to severe systemic damage.
  • Monoclonal component-related diseases present with diverse and challenging clinical features.

Purpose of the Study:

  • To highlight the diagnostic challenges and clinical significance of diseases caused by toxic monoclonal proteins from small B-cell clones.
  • To emphasize the importance of prompt diagnosis and effective therapy for monoclonal component-related diseases.

Main Methods:

  • Review of clinical presentations and pathogenic mechanisms of monoclonal component-related diseases.
  • Discussion of diagnostic techniques for detecting small monoclonal immunoglobulin-producing clones.

Related Experiment Videos

  • Analysis of therapeutic strategies and their impact on patient outcomes.

    • Main Results:

    • Monoclonal proteins can cause systemic damage through aggregation (amyloidosis, deposition disease) or autoantibody activity (cold agglutinin disease, neuropathy).
    • Conditions like POEMS syndrome involve monoclonal proteins contributing to complex multisystem disorders.
    • Small clone size can mask underlying disease, necessitating sensitive detection methods.

    Conclusions:

    • Prompt recognition of clinical signs and sensitive diagnostic approaches are vital for managing monoclonal component-related diseases.
    • Despite suboptimal treatments, advances have improved survival and quality of life for affected patients.
    • Timely diagnosis is key to preventing irreversible organ damage and improving prognosis.